Giusti G, Piccinino F, Sagnelli E, Ruggiero G, Galanti B, Gallo C
Clinic of Infectious Diseases, 1st School of Medicine, University of Naples, Italy.
J Pediatr Gastroenterol Nutr. 1988 Jan-Feb;7(1):17-21. doi: 10.1097/00005176-198801000-00005.
We analyzed retrospectively the effect of immunosuppressive therapy in 139 children with HBsAG-positive chronic active hepatitis (CAH) observed in four liver units in Italy from 1974 to 1982. All children had been observed for at least 12 months. Of these 139 patients, 38 were treated with steroids (prednisolone or prednisone from 1 to 2 mg/kg daily), 78 with combination therapy (prednisolone or prednisone 1 mg/kg daily in combination with azathioprine, 2 mg/kg daily) and 23 were not treated. The outcome of the disease was assessed by evaluating clinical, biochemical, and histological parameters on the basis of preselected criteria. Untreated patients deteriorated more frequently than those treated with steroids (34.8% versus 13.2%, p less than 0.05) or those receiving combination therapy (34.8% versus 10.3%, p less than 0.01). Remission or improvement was observed more frequently in steroid-treated and combination-treated patients than in the untreated ones (p less than 0.001 and p less than 0.01, respectively). At the end of the study, only one untreated patient had died of liver failure. Remission was observed in about 10% of patients in the two groups of treatment, but in the untreated one, this event never occurred. Although this study is retrospective and presents some shortcomings, the data clearly indicate that steroid and combination therapy are not deleterious, and are possibly helpful, to children with HBsAg-positive CAH.(ABSTRACT TRUNCATED AT 250 WORDS)
我们回顾性分析了1974年至1982年在意大利四个肝病治疗中心观察的139例乙肝表面抗原(HBsAg)阳性慢性活动性肝炎(CAH)儿童患者接受免疫抑制治疗的效果。所有儿童均已接受至少12个月的观察。在这139例患者中,38例接受了类固醇治疗(泼尼松龙或泼尼松,每日1至2毫克/千克),78例接受了联合治疗(泼尼松龙或泼尼松每日1毫克/千克,联合硫唑嘌呤每日2毫克/千克),23例未接受治疗。根据预先选定的标准,通过评估临床、生化和组织学参数来评估疾病的转归。未治疗的患者病情恶化的频率高于接受类固醇治疗的患者(34.8%对13.2%,p<0.05)或接受联合治疗的患者(34.8%对10.3%,p<0.01)。接受类固醇治疗和联合治疗的患者缓解或病情改善的频率高于未治疗的患者(分别为p<0.001和p<0.01)。研究结束时,只有1例未治疗的患者死于肝功能衰竭。两组治疗患者中约10%出现缓解,但未治疗组从未出现这种情况。尽管这项研究是回顾性的且存在一些不足,但数据清楚地表明,类固醇和联合治疗对HBsAg阳性CAH儿童无害,且可能有益。(摘要截短于250字)